Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
After finishing at $4.64 in the prior trading day, Cytek BioSciences Inc (NASDAQ: CTKB) closed at $4.7, up 1.29%. In other words, the price has increased by $1.29 from its previous closing price. On the day, 1.44 million shares were traded. CTKB stock price reached its highest trading level at $4.81 during the session, while it also had its lowest trading level at $4.56.
Ratios:
Our goal is to gain a better understanding of CTKB by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.48 and its Current Ratio is at 5.17. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.06.
On May 09, 2025, TD Cowen Downgraded its rating to Hold which previously was Buy but kept the price unchanged to $4.
Goldman Downgraded its Buy to Sell on January 31, 2025, whereas the target price for the stock was revised from $7 to $4.50.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 02 ’25 when McCombe William D. bought 35,000 shares for $2.78 per share. The transaction valued at 97,300 led to the insider holds 55,746 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CTKB now has a Market Capitalization of 600964672 and an Enterprise Value of 364056704. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.05 while its Price-to-Book (P/B) ratio in mrq is 1.59. Its current Enterprise Value per Revenue stands at 1.85 whereas that against EBITDA is -13.55.
Stock Price History:
The Beta on a monthly basis for CTKB is 1.31, which has changed by -0.25641024 over the last 52 weeks, in comparison to a change of 0.16081822 over the same period for the S&P500. Over the past 52 weeks, CTKB has reached a high of $7.30, while it has fallen to a 52-week low of $2.37. The 50-Day Moving Average of the stock is 1.33%, while the 200-Day Moving Average is calculated to be 20.74%.
Shares Statistics:
The stock has traded on average 1.19M shares per day over the past 3-months and 1283200 shares per day over the last 10 days, according to various share statistics. A total of 127.86M shares are outstanding, with a floating share count of 115.96M. Insiders hold about 9.31% of the company’s shares, while institutions hold 62.79% stake in the company. Shares short for CTKB as of 1764288000 were 6927855 with a Short Ratio of 5.80, compared to 1761868800 on 6398689. Therefore, it implies a Short% of Shares Outstanding of 6927855 and a Short% of Float of 7.04.
Earnings Estimates
A detailed examination of Cytek BioSciences Inc (CTKB) is currently in progress, with 2.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$0.04, with high estimates of -$0.04 and low estimates of -$0.04.
Analysts are recommending an EPS of between $0.04 and -$0.01 for the fiscal current year, implying an average EPS of $0.01. EPS for the following year is -$0.01, with 2.0 analysts recommending between -$0.01 and -$0.02.
Revenue Estimates
4 analysts predict $57.09M in revenue for. The current quarter. It ranges from a high estimate of $58.76M to a low estimate of $55.4M. As of. The current estimate, Cytek BioSciences Inc’s year-ago sales were $57.48MFor the next quarter, 4 analysts are estimating revenue of $44.1M. There is a high estimate of $44.9M for the next quarter, whereas the lowest estimate is $42.62M.
A total of 5 analysts have provided revenue estimates for CTKB’s current fiscal year. The highest revenue estimate was $198.11M, while the lowest revenue estimate was $196M, resulting in an average revenue estimate of $196.71M. In the same quarter a year ago, actual revenue was $200.45MBased on 5 analysts’ estimates, the company’s revenue will be $207.45M in the next fiscal year. The high estimate is $211.82M and the low estimate is $203.3M.
